'Inspired' by Ipsen's mission, Sandra Silvestri joins as next CMO; Exicure's slide continues with CEO, CFO exits
Ipsen is waiting on an FDA decision this summer for what could be the first drug to treat an ultra-rare bone disease called fibrodysplasia ossificans progressiva (FOP) — and if all goes well, it will have a new chief medical officer to take it across the finish line.
Sandra Silvestri is joining the company from Sanofi on May 5, Ipsen announced earlier this week. An endocrinologist by training, her resume boasts long tenures at both Eli Lilly and Sanofi, where she was most recently the French pharma’s senior VP and CMO of its General Medicines global business unit and global head of medical affairs capabilities at its Centre of Excellence and Medical Hub.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.